11/26/14


S1 Biopharma, which is developing a combined therapy of existing drugs for female sexual dysfunction, lowered the proposed deal size for its upcoming IPO on Wednesday. The New York, NY-based company now plans to raise $23 million by offering 1.8 million units, which include one common share as well as one Series A and one Series B warrant, at a price range of $12 to $14. The company had previously filed to offer 2.8 million common shares at a range of $12 to $14. At the midpoint of the revised range, S1 Biopharma will raise -36% fewer proceeds than previously anticipated and now commands a ...more


Keywords: SXB

11/24/14


Vyrix Pharmaceuticals, a biotech developing an oral treatment for premature ejaculation, withdrew its plans for an initial public offering on Monday citing market conditions. The company originally filed for a $30 million IPO in April 2014. The company is owned by Ampio Pharmaceuticals (NYSEMKT: AMPE). A female sexual dysfunction biotech, S1 Biopharma ([SXB]), had set terms to raise $36 million earlier this month but postponed its offering. The Greenwood Village, CO-based company was founded in 2013. VYRX. Aegis Capital and Fordham Financial Management were set to be the joint ...more


Keywords: VYRX, AMPE, Biotech

11/24/14


Polar Star Realty Trust, a REIT formed to own office and industrial property in Norway and Sweden, announced terms for its IPO on Monday. The New York, NY-based company plans to raise $500 million by offering 43.5 million shares at a price range of $10 to $13. At the midpoint of the proposed range, Polar Star Realty Trust would command a fully diluted market value of $800 million. The year's two largest REIT IPOs, Paramount Group ([PGRE]) and STORE Capital ([STOR]), priced last week and trade up 5% and 7% respectively. Polar Star Realty Trust, which was founded in 1999 and ...more


Keywords: PSRT, STOR, PGRE

11/21/14 Analyst IPO Blog


9 companies went public in the past week as the IPO market raised $3.5 billion. At 26 deals, November issuance fell one IPO short of last year, unless CVSL manages to price next week. November IPOs raised $7.2 billion and averaged 19% from the offer price, including 4% after the first day. Two companies rose over 100% on their debut, the sixth and seventh IPOs of 2014 to do so. Retinal implant maker Second Sight Medical Products spiked 122% on its first day and fast casual burger chain The Habit ...more


Keywords: HABT, EYES, CNV, PGRE, ADAM, STOR, NEOT, SKIS, NEFF, EHIC

Archived News Headlines
Performance Disclosure: Past performance does not guarantee future results. The performance data quoted represents past performance and current returns may be lower or higher. The investment return and principal value of an investment will fluctuate so that an investor’s shares, when redeemed, may be worth more or less than the original cost. Investors should consider the investment objectives, risks, charges and expenses carefully before investing.

As stated in the Prospectus, the total annual operating expenses for the Fund was 3.48%. The Adviser has contractually agreed to keep net expenses from exceeding 2.50% of the Fund’s average daily net assets for at least a year from the date of the Prospectus and for an indefinite period thereafter subject to annual re-approval of the agreement by the Board of Trustees. An investor cannot invest directly in an index. Index returns do not represent Fund returns. The Index does not charge management fees or brokerage expenses, nor does the Index lend securities, and no revenues from securities lending were added to the performance shown.

Definitions: Net Asset Value (NAV) of the fund is calculated by dividing the total value of all the securities in its portfolio, less any liabilities, by the number of fund shares outstanding. Market Price is current value at which an asset or service can be bought or sold. Premium/Discount is provided to show the comparison of the daily net asset value (NAV) and the midpoint of the closing bid/ask for each of the funds. The Renaissance IPO Index® (IPOUSA) is a stock market index based upon a portfolio of U.S.-listed newly public companies that includes securities prior to their inclusion in core U.S. equity portfolios. The Renaissance International IPO Index® (IPOXUS) is a stock market index based upon a portfolio of newly public companies listed on non-U.S. exchanges. The S&P 500® Index (SPX) is a stock market index based on the market capitalizations of 500 large companies whose common stock is publicly traded on the NYSE.

Risk Disclosure: Investments in the Renaissance IPO ETF, symbol "IPO", the Renaissance International IPO ETF, symbol "IPOS" (the “ETFs”), and the Global IPO Fund, symbol "IPOSX" (the “Mutual Fund”) are subject to investment risk, including possible loss of the principal amounts invested. The ETFs and the Mutual Fund (the “Funds”) invest in companies that have recently completed initial public offerings. These stocks are unseasoned equities lacking trading history, a track record of reporting to investors and widely available research coverage which many result in extreme price volatility. Due to a greater number of IPOs in certain segments, the Funds may also be subject to information technology and financial sector risk, small and mid-capitalization company risk, and, for the Renaissance International IPO ETF, emerging markets risk. The Funds may hold securities in the form of Depository Receipts, REITs, and Partnership Units which have greater risks than common shares. The strategies have high portfolio turnover and securities lending risks. The returns of the ETFs may not match the return of the respective indices. The ETFs are classified as non-diversified investment companies subject to concentration risk.

Prospectus: Investors should consider the investment objectives, risks, charges and expenses carefully before investing. For a prospectus and/or summary prospectus with this and other information, please visit www.renaissancecapital.com. Read the prospectus carefully before investing. Renaissance Capital Investments, Inc., distributor for the Mutual Fund. Foreside Fund Services, LLC, distributor for the ETFs, 1-866-486-6645.
Attribution Policy: The information contained herein is proprietary and copyrighted. The media is welcome to use our information and ideas, provided that the following sourcing is included: Renaissance Capital - manager of IPO-focused ETFs.
Investment Disclosure: The information and opinions expressed herein were prepared by Renaissance Capital's research analysts and do not constitute an offer to buy or sell any security. Renaissance Capital, the Renaissance IPO ETF (symbol: IPO), the Renaissance International IPO ETF (symbol: IPOS), or the Global IPO Fund (symbol: IPOSX), may have investments in securities of companies mentioned.